Pfizer signs $340 million licensing pact with GlycoMimetics

10/11/2011 | American City Business Journals

GlycoMimetics entered a global licensing agreement with Pfizer for GMI-1070, an experimental treatment for vaso-occlusive crisis in patients with sickle cell disease. The deal calls for GlycoMimetics to complete the drug's Phase II study, then turn over further development and commercialization to Pfizer. GlycoMimetics is entitled to upfront, milestone and royalty payments worth as much as $340 million.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
PacificSource
Springfield, OR
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA